Xilio Therapeutics (XLO) Net Income Growth (3y) (2023 - 2026)

Xilio Therapeutics (XLO) Net Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,861.65 Bn 66,861.36 Bn - 9.16%
2 Nanobiotix 1,910.87 Bn 1,910.81 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.90 Bn 61.14 Bn 3.31 Bn -3.84%
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 55.83 Bn 50.65 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.46 Bn 37.46 Bn - -
10 Xilio Therapeutics 144.35 Mn -5.95 Mn - 15.87%

Historic Data

Download Data
DateValue
Mar 31, 2026 15.87%
Dec 31, 2025 21.39%
Sep 30, 2025 53.93%
Jun 30, 2025 16.59%
Mar 31, 2025 13.41%
Dec 31, 2024 10.88%
Sep 30, 2024 22.36%
Jun 30, 2024 13.65%
Mar 31, 2024 -2.11%
Dec 31, 2023 3.74%
Sep 30, 2023 -5.51%